Q3 EPS Forecast for Abeona Therapeutics Lifted by Analyst

Key Points

• Zacks Small Cap has increased its Q3 2025 EPS estimate for Abeona Therapeutics from ($0.18) to ($0.17) per share, while the consensus estimate for the full year stands at ($1.16) per share.
• Abeona Therapeutics reported earnings of $1.71 per share for the last quarter, significantly exceeding the consensus estimate of ($0.39) per share, although its revenue fell short of expectations.
• Several analysts have provided mixed ratings for Abeona Therapeutics, with five analysts rating it as a "Buy" while others have adjusted price targets and ratings, indicating a diverse outlook for the stock.

Abeona Therapeutics Inc. (NASDAQ:ABEO - Free Report) - Stock analysts at Zacks Small Cap upped their Q3 2025 earnings per share estimates for shares of Abeona Therapeutics in a research note issued on Monday, August 18th. Zacks Small Cap analyst D. Bautz now forecasts that the biopharmaceutical company will post earnings of ($0.17) per share for the quarter, up from their previous estimate of ($0.18). The consensus estimate for Abeona Therapeutics' current full-year earnings is ($1.16) per share. Zacks Small Cap also issued estimates for Abeona Therapeutics' Q4 2025 earnings at $0.10 EPS.

A number of other equities analysts also recently weighed in on the company. HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Abeona Therapeutics in a report on Monday, August 18th. Oppenheimer upped their target price on Abeona Therapeutics from $19.00 to $20.00 and gave the company an "outperform" rating in a report on Friday, August 15th. Alliance Global Partners reiterated a "buy" rating on shares of Abeona Therapeutics in a report on Thursday, May 15th. Stifel Nicolaus dropped their target price on Abeona Therapeutics from $21.00 to $20.00 and set a "buy" rating on the stock in a report on Friday, May 16th. Finally, Wall Street Zen downgraded Abeona Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 15th. Five equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $19.50.

Abeona Therapeutics Stock Down 0.3%

Shares of ABEO traded down $0.02 during trading hours on Thursday, reaching $6.99. The company's stock had a trading volume of 141,723 shares, compared to its average volume of 1,015,418. The firm has a market cap of $358.45 million, a price-to-earnings ratio of 9.96 and a beta of 1.55. Abeona Therapeutics has a 1-year low of $3.93 and a 1-year high of $7.54. The company has a quick ratio of 6.65, a current ratio of 6.73 and a debt-to-equity ratio of 0.09. The company has a 50 day moving average of $6.32 and a two-hundred day moving average of $5.80.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last issued its earnings results on Thursday, August 14th. The biopharmaceutical company reported $1.71 earnings per share for the quarter, beating analysts' consensus estimates of ($0.39) by $2.10. The business had revenue of $0.40 million during the quarter, compared to analyst estimates of $21.71 million.

Institutional Investors Weigh In On Abeona Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC boosted its position in Abeona Therapeutics by 894.8% during the fourth quarter. Jane Street Group LLC now owns 131,478 shares of the biopharmaceutical company's stock worth $732,000 after purchasing an additional 118,262 shares during the period. Wellington Management Group LLP bought a new stake in Abeona Therapeutics during the fourth quarter worth approximately $520,000. Squarepoint Ops LLC bought a new stake in Abeona Therapeutics during the fourth quarter worth approximately $67,000. Northern Trust Corp boosted its position in Abeona Therapeutics by 6.6% during the fourth quarter. Northern Trust Corp now owns 184,929 shares of the biopharmaceutical company's stock worth $1,030,000 after purchasing an additional 11,478 shares during the period. Finally, Bank of America Corp DE boosted its position in Abeona Therapeutics by 16.7% during the fourth quarter. Bank of America Corp DE now owns 264,439 shares of the biopharmaceutical company's stock worth $1,473,000 after purchasing an additional 37,774 shares during the period. Institutional investors own 80.56% of the company's stock.

Insider Transactions at Abeona Therapeutics

In other Abeona Therapeutics news, Director Mark Alvino sold 13,093 shares of the company's stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $5.86, for a total transaction of $76,724.98. Following the completion of the sale, the director owned 77,252 shares of the company's stock, valued at $452,696.72. This represents a 14.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Brendan M. O'malley sold 17,428 shares of the company's stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $5.86, for a total value of $102,128.08. Following the sale, the senior vice president directly owned 360,817 shares of the company's stock, valued at $2,114,387.62. The trade was a 4.61% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 229,626 shares of company stock valued at $1,417,827 in the last ninety days. 5.40% of the stock is currently owned by insiders.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.